Health
Virus drug benefit only marginal: study – Education – Australian Associated Press
Researchers say a new study of Gilead Sciences’ remdesivir raises questions about the efficacy of the drug in the treatment of COVID-19.
Moderately ill COVID-19 patients had their condition improve after a 5-day course of Gilead Sciences Inc’s remdesivir but the drug did not significantly shorten hospital stays and a 10-day course did not show a benefit, according to new data.
The drug, which was shown in a trial of severely ill COVID-19 patients to shorten their hospital recovery time, has been at the forefront of the battle against the pandemic.
The 600-patient analysis, published on Friday by the Journal of the American Medi…
-
General14 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Noosa News20 hours agoPerth Royal Show vendors upset by price hikes, say crowds are down in 2025
-
Business22 hours agoBell Potter names the best ASX shares to buy in October
-
General19 hours agoAustralia welcomes Gaza peace progress, hostage release